Publications
The HDAC6-specific inhibitor AVS100 blocks M2 polarization of tumor associated macrophages and potentiates immunotherapy in preclinical tumor models
Reprogramming Macrophages with HDAC6 Inhibitors for Anti-cancer Macrophage-based Cell Therapy
Inhibition of HDAC6 and HDAC11 Has an Opposite Effect on Inflammation and the Functional Phenotype of Macrophages in the Tumor Microenvironment
Discovery of a New Isoxazole-3-hydroxamate Based Histone Deacetylase 6 Inhibitor SS-208 (AVS100) with Antitumor Activity in Syngeneic Melanoma Mouse Models
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma
Reprogramming Macrophages with HDAC6 Inhibitors for Anti-cancer Macrophage-based Cell Therapy
Inhibition of HDAC6 and HDAC11 Has an Opposite Effect on Inflammation and the Functional Phenotype of Macrophages in the Tumor Microenvironment
Discovery of a New Isoxazole-3-hydroxamate Based Histone Deacetylase 6 Inhibitor SS-208 (AVS100) with Antitumor Activity in Syngeneic Melanoma Mouse Models
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma
